Meeting
2014 ASCO Annual Meeting
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
Authors
Jordi Bruix
BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
Jordi Bruix , Richard S. Finn , Masatoshi Kudo , Josep M. Llovet , Shukui Qin , Marie-Aude Le Berre , Andrea Wagner , Ann-Lii Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01774344
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4156^)
DOI
10.1200/jco.2014.32.15_suppl.tps4156
Abstract #
TPS4156^
Poster Bd #
237A
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
First Author: Richard S. Finn
Poster
2013 ASCO Annual Meeting
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
First Author: Ann-Lii Cheng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
First Author: Richard S. Finn
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
First Author: Richard S. Finn